Artículo de revista
Non-dystrophic myotonia Chilean cohort with predominance of the SCN4A Gly1306Glu variant
Fecha
2020Registro en:
Neuromuscular Disorders 30 (2020) 554–561
10.1016/j.nmd.2020.04.006
Autor
Ávila Smirnow, Daniela
Vargas Leal, Carmen
Beytía Reyes, María de los Ángeles
Cortés Zepeda, Rocío
Escobar, Raúl G.
Kleinsteuber Saa, Karin
Lagos Lucero, Marcela
Avaria Benapres, María de los Ángeles
Padilla Pérez, Oslando
Casar Leturia, Juan Carlos
Mellado Sagredo, Cecilia
Sternberg, Damien
Institución
Resumen
Non-dystrophic myotonias are a group of rare neuromuscular diseases linked to SCN4A or CLCN1 . Among the subtypes, myotonia
permanens, associated with the Gly1306Glu variant of SCN4A , is a relatively less frequent but more severe form. Most reports of nondystrophic
myotonias describe European populations. Therefore, to expand the genetic and phenotypic spectrum of this disorder, we evaluated
30 Chilean patients with non-dystrophic myotonias for associated variants and clinical characteristics. SCN4A variants were observed in 28
(93%) of patients, including 25 (83%) with myotonia permanens due to the Gly1306Glu variant. Myotonia permanens was inherited in 24
(96%) patients; the mean age of onset was 6 months, and the initial symptoms were orbicularis oculi myotonia in 17 (74%) patients and
larynx myotonia in 12 (52%) patients. The extraocular muscles were involved in 11 (44%) patients, upper limbs in 20 (80%), and lower
limbs in 21 (84%). Thirteen (52%) patients experienced recurrent pain and 10 (40%) patients reported limitations in daily life activities.
Carbamazepine reduced myotonia in eight treated patients. The high frequency of the Gly1306Glu variant in SCN4A in Chilean patients
suggests a founder effect and expands its phenotypic spectrum.